why choose us

First received: October 04, 2022

Clinical Trial: Combination Immunotherapy in Colorectal Cancer

Study Status: ACTIVE_NOT_RECRUITING

Recruit Status: ACTIVE_NOT_RECRUITING

Condition: Colorectal Neoplasms

Study Type: INTERVENTIONAL


Official Title: Novel Exploratory Study to Test Combination of Botensilimab and Balstilimab Immunotherapy in Resectable Colorectal Cancer Patients

Brief Summary: This is a pilot study to see whether a combination of two investigational drugs that target the immune system can be given to people with colorectal cancer before surgically removing the tumor.This study is also being done to see what side effects this combination of drugs has and what effect they have on colorectal cancer.The two monoclonal antibodies are balstilimab, a programmed cell death protein 1 (PD-1) inhibitor, and botensilimab, a cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitor.Participants…

Read more